Optinose US Inc.
Quick facts
Phase 3 pipeline
- OPN-375 · Gastroenterology
OPN-375 is a selective serotonin 5-HT4 receptor agonist that enhances gastric motility and accelerates gastric emptying.
Phase 1 pipeline
Competitive intelligence
For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:
Frequently asked questions about Optinose US Inc.
What is Optinose US Inc.'s pipeline?
Optinose US Inc. has 1 drugs in Phase 3, 0 in Phase 2, 1 in Phase 1. Late-stage candidates include OPN-375.
Related
- Sector hub: All tracked pharma companies